LENSAR (LNSR) AI Stock Analysis

• Market Cap: $139.39M
• Dividend Yield: N/A
• Average Volume (3M): 58.95K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.86
• Revenue Growth: 21.02%
• EPS Growth: -200.88%
• Country: US
• Employees: 140
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.31
• Shares Outstanding: 11,944,546
• 10 Day Avg. Volume: 51,870
• 30 Day Avg. Volume: 58,950
• PEG Ratio: -0.03
• Price to Book (P/B): 21.18
• Price to Sales (P/S): 1.92
• P/FCF Ratio: -42.36
• Enterprise Value/Market Cap: 1.07
• Enterprise Value/Revenue: 2.51
• Enterprise Value/Gross Profit: 5.49
• Enterprise Value/Ebitda: -11.74
• 1Y Price Target: $15.00
• Price Target Upside: 29.20% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: $12.00 ▲(3.36% Upside)

LENSAR's overall stock score is primarily impacted by its weak financial performance, which is the most significant factor. While technical indicators suggest some positive momentum, the negative valuation metrics and ongoing financial challenges weigh heavily on the score. The supportive corporate event provides some stability but does not significantly alter the overall assessment.

Positive Factors

Revenue Growth

The company has demonstrated strong revenue growth, indicating successful market penetration and increasing demand for its products.

Shareholder Support

Strong shareholder support for the board and auditors suggests stability in corporate governance, which is crucial for long-term strategic execution.

Cash Flow Efficiency

Positive free cash flow growth indicates improved cash management, which can support operational needs and strategic investments.

Negative Factors

Consistent Net Losses

Ongoing net losses and negative margins highlight operational inefficiencies, which could hinder long-term profitability and sustainability.

Negative Equity

Negative equity suggests potential solvency issues, posing a risk to financial stability and limiting the company's ability to raise capital.

Operating Cash Flow Deficit

Negative operating cash flow indicates that the company is not generating sufficient cash from operations, which could impact its ability to fund growth initiatives.

LENSAR Business Overview & Revenue Model

Company Description

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its LENSAR Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company was incorporated in 2004 and is headquartered in Orlando, Florida.

How the Company Makes Money

LENSAR generates revenue through the sale of its proprietary LENSAR Laser Systems and the associated consumables used during cataract surgeries, such as disposable tips and patient-specific software. The company also earns income from service contracts and maintenance agreements for its equipment. Significant partnerships with ophthalmic surgery centers and hospitals play a crucial role in expanding its market reach and driving sales. Additionally, LENSAR may benefit from reimbursements from insurance providers for procedures performed using its technology, enhancing its overall revenue potential.

LENSAR Financial Statement Overview

Summary

LENSAR's financial performance is weak, with consistent net losses and negative profit margins. The balance sheet shows negative stockholders' equity and potential solvency issues. Despite minor improvements in revenue and free cash flow growth, the overall financial health remains precarious.

Income Statement

LENSAR's income statement reveals a challenging financial position with consistent net losses and negative profit margins. The TTM data shows a slight revenue growth of 2.28%, but the company continues to struggle with high net loss margins of -84.49%. Gross profit margins have decreased slightly over the years, indicating pressure on profitability. The EBIT and EBITDA margins remain negative, highlighting ongoing operational challenges.

Balance Sheet

The balance sheet reflects a concerning financial structure with negative stockholders' equity in the TTM period, resulting in a negative debt-to-equity ratio. This indicates potential solvency issues. The return on equity is alarmingly high at 51.79% in the TTM, driven by negative equity, which is not sustainable. The equity ratio has deteriorated, suggesting increased financial risk.

Cash Flow

Cash flow analysis shows some positive trends, with free cash flow growth of 29.25% in the TTM. However, operating cash flow remains negative, and the operating cash flow to net income ratio is unfavorable at -0.17. The free cash flow to net income ratio is slightly positive, indicating some efficiency in cash management despite ongoing losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	59.14M	53.49M	42.16M	35.36M	34.46M	26.38M
Gross Profit	27.06M	25.85M	21.11M	19.95M	17.83M	14.07M
EBITDA	-12.65M	-3.00M	-8.71M	-16.77M	-16.89M	-15.36M
Net Income	-51.52M	-31.40M	-14.38M	-19.91M	-19.60M	-19.77M
Balance Sheet
Total Assets	70.20M	66.30M	69.58M	55.84M	66.47M	79.12M
Cash, Cash Equivalents and Short-Term Investments	16.87M	22.45M	24.06M	14.67M	31.64M	40.60M
Total Debt	2.88M	2.61M	2.31M	2.80M	3.31M	3.81M
Total Liabilities	82.33M	47.65M	22.41M	13.86M	11.59M	11.91M
Stockholders Equity	-12.12M	18.65M	47.18M	41.98M	54.88M	67.21M
Cash Flow
Free Cash Flow	-11.88M	-2.43M	-9.89M	-14.97M	-9.32M	-14.16M
Operating Cash Flow	-11.79M	-2.27M	-9.66M	-14.86M	-8.97M	-13.79M
Investing Cash Flow	-969.00K	-2.16M	-4.16M	-115.00K	-354.00K	-326.00K
Financing Cash Flow	9.96M	78.00K	19.76M	-1.99M	361.00K	50.00M

LENSAR Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 11.61
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LNSR, the sentiment is Positive. The current price of 11.61 is below the 20-day moving average (MA) of 11.74, above the 50-day MA of 11.18, and below the 200-day MA of 12.54, indicating a neutral trend. The MACD of 0.11 indicates Positive momentum. The RSI at 54.44 is Neutral, neither overbought nor oversold. The STOCH value of 36.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LNSR.

LENSAR Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SGHT	58 Neutral	$398.12M	-8.41	-57.91%	―	-4.39%	11.70%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
HYPR	50 Neutral	$96.33M	-1.89	-94.03%	―	-20.10%	7.87%
LNSR	49 Neutral	$139.39M	-2.66	-422.35%	―	21.02%	-200.88%
RPID	48 Neutral	$143.83M	-3.25	-68.83%	―	16.63%	10.43%
TELA	44 Neutral	$48.54M	-1.23	―	―	12.24%	47.45%
RCEL	43 Neutral	$100.02M	-1.81	-1746.27%	―	20.59%	18.61%

LENSAR Corporate Events

LENSAR stockholders approve directors and auditor at meeting

On December 18, 2025, LENSAR, Inc. held its annual meeting of stockholders with approximately 88% of the company’s total voting power represented in person or by proxy. At the meeting, shareholders elected Nicholas T. Curtis, Todd B. Hammer and Aimee S. Weisner as Class II directors to serve until the 2028 annual meeting, and ratified the appointment of PricewaterhouseCoopers LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025, signaling strong shareholder support for the current board slate and audit firm arrangement.

The most recent analyst rating on (LNSR) stock is a Sell with a $10.00 price target. To see the full list of analyst forecasts on LENSAR stock, see the LNSR Stock Forecast page.

LENSAR Announces Virtual Annual Meeting Plans

LENSAR, Inc. has announced that its 2025 annual meeting of stockholders is scheduled for December 18, 2025, to be held virtually. This meeting will only occur if the proposed merger with Alcon Research, LLC is not completed before the meeting date. If the merger is completed, LENSAR will become a wholly owned subsidiary of Alcon, and the meeting will not take place. Stockholders are advised of revised deadlines for submitting proposals and nominations, which must be received by October 31, 2025.

The most recent analyst rating on (LNSR) stock is a Hold with a $12.00 price target. To see the full list of analyst forecasts on LENSAR stock, see the LNSR Stock Forecast page.